About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
Events🚀 Cardiawave contributes to Medicen Paris Region’s “Regulatory by Design” event on Oct. 21! Oct 9, 2025 READ MORE
EventsCardiawave featured by LSI Europe ‘25 as one of the selected innovators presenting in London this September! Aug 12, 2025 READ MORE
About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
